Information Provided By:
Fly News Breaks for March 10, 2015
BAX, CTIC, INCY
Mar 10, 2015 | 08:07 EDT
After CTI BioPharma (CTIC) and Baxter (BAX) reported positive data for its JAK2/FLT3 inhibitor, pacritinib, which competes with Incyte's (INCY) Jakafi, JMP Securities does not expect pacritinib to gain much share, as the firm thinks it has "a cumbersome safety profile." JMP Securities reiterates a $97 price target and Outperform rating on Incyte.
News For INCY;CTIC;BAX From the Last 2 Days
INCY
INCY
I agree to the thefly.com's disclaimer & terms of use
Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.